Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (NYSE: BLCO) will present 45 scientific presentations and posters at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10–13, 2026. Topics span IOLs, MIGS, dry eye therapies, osmolarity testing, excimer laser trabeculostomy and real-world outcomes.
Events include company-hosted sessions April 9–11 and multiple paper and poster presentations reporting clinical evaluations, real-world evidence and device performance across the company’s portfolio.
Bausch + Lomb (NYSE: BLCO) will release its first-quarter 2026 financial results on Wednesday, April 29, 2026, and will host a conference call and live webcast at 8 a.m. ET.
All presentation materials will be posted on the company's Investor Relations website prior to the call. Replay access will be available through May 13, 2026, with passcode 53393.
Bausch + Lomb (NYSE:BLCO) announced positive 24-month pivotal U.S. trial results for the implant-free ELIOS System for open-angle glaucoma. Key outcomes: 76% of patients achieved ≥20% unmedicated IOP reduction, mean unmedicated DIOP fell by 7.4 mmHg, and 82% were medication-free at 23 months.
The ELIOS procedure reported no intraoperative complications and a postoperative adverse event rate similar to cataract surgery. ELIOS is CE marked in Europe but has not been reviewed by the FDA in the U.S.
Bausch + Lomb (NYSE: BLCO) announced an R&D “Teach-in” webinar on March 23, 2026 at 1:30 p.m. ET covering two glaucoma programs: BL1107, a medication in development targeting vision loss plus intraocular pressure, and ELIOS™, an implant-free MIGS approach commercialized in Europe with anticipated U.S. launch in 2H 2026.
The live event will feature R&D and senior executives and will be hosted by Wells Fargo; a replay will be posted on the company Investor Relations website.
Bausch + Lomb (NYSE: BLCO) cites a new global review in Ophthalmology and Therapy showing a lifestyle-driven rise in noninfectious ocular redness from digital eye strain, dry eye, allergies and environment. The review highlights LUMIFY (brimonidine tartrate 0.025%) as a differentiated OTC option with a selective α2 mechanism, no tachyphylaxis over 29 days, and virtually no rebound redness. It also notes a preservative-free brimonidine 0.025% formulation introduced by the company in 2025 with comparable efficacy and tolerability. The paper calls for more patient education on safe OTC redness treatments.
Bausch + Lomb (NYSE: BLCO) reported Q4 2025 revenue $1.405B (up 10% reported, 7% constant currency) and FY 2025 revenue $5.101B (up 6% reported, 5% CC).
GAAP net loss was $58M Q4 and $360M FY; adjusted EBITDA was $326M Q4 and $858M FY. The company guided 2026 revenue $5.375B–$5.475B and Adj. EBITDA ex-IPR&D $1.00B–$1.05B.
Operational highlights included MIEBO Q4 sales $112M, a $1.1B dry-eye portfolio in 2025, premium IOL recovery, ongoing clinical trial recruitment, cash of $397M, and a webcast replay available through March 4, 2026.
Bausch + Lomb (NYSE: BLCO) will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET to discuss results and provide a business update.
Materials will be posted on the Investor Relations website before the call. A replay will be available until March 4, 2026.
- Date: Wednesday, Feb. 18, 2026
- Time: 8:00 a.m. ET
- Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392
- Participant dial-in (North America): +1 (888) 506-0062
- Participant dial-in (International): +1 (973) 528-0011
- Access code: 923960
- Replay dial-in (North America): +1 (877) 481-4010; Replay passcode: 53392
Bausch + Lomb (NYSE: BLCO) announced a partnership with Glaucoma Research Foundation and The Glaucoma Foundation for Glaucoma Awareness Month in January 2026 to raise awareness and fund research into glaucoma, which affects about four million people in the U.S.
Key actions: Bausch + Lomb will launch its fifth annual fundraising challenge and match donations dollar-for-dollar up to $20,000 during January; it will also sponsor a month-long social media campaign spotlighting a glaucoma patient or advocate each day. All proceeds will support glaucoma research and education.
Bausch + Lomb (NYSE: BLCO) closed a refinancing under a Fourth Amendment to its credit agreement, establishing $2,802,125,000 of Replacement Term B loans to refinance outstanding term B loans due 2031 and 2028.
The Replacement Term Loans carry a 1.00% annual amortization with the first installment due June 30, 2026, and mature on January 15, 2031. The applicable margins are 3.75% over term SOFR or 2.75% over alternate base rate, representing a 50 bps reduction versus the prior 2031 tranche and a 25 bps reduction versus the 2028 tranche; the 2028 loans receive an effective five-plus year maturity extension to 2031.
Bausch + Lomb (NYSE: BLCO) announced that Chairman and CEO Brent Saunders, CFO Sam Eldessouky, and CMO & Head of R&D Yehia Hashad, MD will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026 at 1:30 p.m. PT (4:30 p.m. ET).
A live webcast and an audio archive will be available on the company Investor Relations website at http://ir.bausch.com/investors/events-presentations.